-+ 0.00%
-+ 0.00%
-+ 0.00%

Castle Biosciences Signs Collaboration And License Agreement With SciBase To Develop Atopic Dermatitis Flare Prediction Test Using Electrical Impedance Spectroscopy Technology

Benzinga·06/16/2025 20:32:11
Listen to the news

Castle Biosciences, Inc. (NASDAQ:CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB ("SciBase") utilizing SciBase's Electrical Impedance Spectroscopy technology which includes both desktop and point-of-care instruments. The initial goal of the collaboration is to advance the development of a diagnostic test that predicts flares in patients diagnosed with atopic dermatitis (AD).